| scholarly article | Q13442814 |
| P50 | author | Megan Othus | Q75025967 |
| Elihu Estey | Q96145785 | ||
| P2093 | author name string | Roland B Walter | |
| Kelda M Gardner | |||
| Tara L Chen | |||
| Lauren J Markle | |||
| P2860 | cites work | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 |
| Chemotherapy resistance in acute myeloid leukaemia | Q34252879 | ||
| The role of drug efflux pumps in acute myeloid leukemia. | Q34769834 | ||
| Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment | Q35565648 | ||
| Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study | Q35750986 | ||
| Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies | Q35817464 | ||
| Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations | Q36621967 | ||
| Adaptive clinical trials in oncology | Q37953783 | ||
| P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors | Q40070493 | ||
| A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials | Q40781868 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses | Q44265497 | ||
| Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells | Q44909361 | ||
| Dose-finding based on efficacy-toxicity trade-offs | Q45038149 | ||
| Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. | Q54104948 | ||
| P433 | issue | 11 | |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| cyclosporine | Q367700 | ||
| etoposide | Q418817 | ||
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | 2534-2536 | |
| P577 | publication date | 2013-03-27 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study | |
| P478 | volume | 54 |
| Q50639190 | An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. |
| Q38654251 | Implementing the EffTox dose-finding design in the Matchpoint trial. |
| Q38973323 | Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy |
| Q58580490 | Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms |
| Q43442213 | Reversing multidrug resistance (MDR1, ABCB1) in acute myeloid leukemia: back to the ABCs |
Search more.